252 related articles for article (PubMed ID: 31142503)
1. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.
Conlon KC; Potter EL; Pittaluga S; Lee CR; Miljkovic MD; Fleisher TA; Dubois S; Bryant BR; Petrus M; Perera LP; Hsu J; Figg WD; Peer CJ; Shih JH; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
Clin Cancer Res; 2019 Aug; 25(16):4945-4954. PubMed ID: 31142503
[TBL] [Abstract][Full Text] [Related]
2. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
[TBL] [Abstract][Full Text] [Related]
3. IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56
Dubois S; Conlon KC; Müller JR; Hsu-Albert J; Beltran N; Bryant BR; Waldmann TA
Cancer Immunol Res; 2017 Oct; 5(10):929-938. PubMed ID: 28842470
[TBL] [Abstract][Full Text] [Related]
4. A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.
Miller JS; Morishima C; McNeel DG; Patel MR; Kohrt HEK; Thompson JA; Sondel PM; Wakelee HA; Disis ML; Kaiser JC; Cheever MA; Streicher H; Creekmore SP; Waldmann TA; Conlon KC
Clin Cancer Res; 2018 Apr; 24(7):1525-1535. PubMed ID: 29203590
[No Abstract] [Full Text] [Related]
5. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.
Margolin K; Morishima C; Velcheti V; Miller JS; Lee SM; Silk AW; Holtan SG; Lacroix AM; Fling SP; Kaiser JC; Egan JO; Jones M; Rhode PR; Rock AD; Cheever MA; Wong HC; Ernstoff MS
Clin Cancer Res; 2018 Nov; 24(22):5552-5561. PubMed ID: 30045932
[No Abstract] [Full Text] [Related]
7. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.
Doedens AL; Rubinstein MP; Gross ET; Best JA; Craig DH; Baker MK; Cole DJ; Bui JD; Goldrath AW
Cancer Immunol Res; 2016 Sep; 4(9):799-811. PubMed ID: 27485135
[TBL] [Abstract][Full Text] [Related]
8. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice.
Song Y; Liu Y; Hu R; Su M; Rood D; Lai L
Mol Cancer Ther; 2016 Oct; 15(10):2413-2421. PubMed ID: 27474151
[TBL] [Abstract][Full Text] [Related]
10. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
11. Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors.
Kalwak K; Ussowicz M; Gorczyńska E; Turkiewicz D; Toporski J; Dobaczewski G; Latos-Grazyńska E; Ryczan R; Noworolska-Sauren D; Chybicka A
J Interferon Cytokine Res; 2003 Apr; 23(4):173-81. PubMed ID: 12856329
[TBL] [Abstract][Full Text] [Related]
12. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.
Ng S; Deng J; Chinnadurai R; Yuan S; Pennati A; Galipeau J
Cancer Res; 2016 Oct; 76(19):5683-5695. PubMed ID: 27488533
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.
Hekim C; Ilander M; Yan J; Michaud E; Smykla R; Vähä-Koskela M; Savola P; Tähtinen S; Saikko L; Hemminki A; Kovanen PE; Porkka K; Lee FY; Mustjoki S
Cancer Immunol Res; 2017 Feb; 5(2):157-169. PubMed ID: 28073775
[TBL] [Abstract][Full Text] [Related]
15. IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
Front Immunol; 2020; 11():868. PubMed ID: 32508818
[TBL] [Abstract][Full Text] [Related]
16. Inosine Acedoben Dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications.
Rumel Ahmed S; Newman AS; O'Daly J; Duffy S; Grafton G; Brady CA; John Curnow S; Barnes NM; Gordon J
Int Immunopharmacol; 2017 Jan; 42():108-114. PubMed ID: 27912146
[TBL] [Abstract][Full Text] [Related]
17. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood.
Sneller MC; Kopp WC; Engelke KJ; Yovandich JL; Creekmore SP; Waldmann TA; Lane HC
Blood; 2011 Dec; 118(26):6845-8. PubMed ID: 22067383
[TBL] [Abstract][Full Text] [Related]
18. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
[TBL] [Abstract][Full Text] [Related]
19. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
20. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
